Bicarbonate

Bicarbonate

SCHEMBL362971

CC(C)(C)N(C(=O)c1ncc(-c2nc(N3CCOCC3)c3ncn(C4CCCCO4)c3n2)c(C(F)(F)F)n1)C(C)(C)C.O=C(O)O.O=C(O)O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.39
PIK3CA P42336 13/20 0.37
MTOR P42345 12/20 0.37
PIK3CG P48736 8/20 0.37
YTHDC1 Q96MU7 1/20 0.34
PIK3R1 P27986 3/20 0.34
RICTOR Q6R327 2/20 0.34
RPTOR Q8N122 2/20 0.34
MAPKAP1 Q9BPZ7 2/20 0.34
MLST8 Q9BVC4 2/20 0.34
PIK3CD O00329 1/20 0.34
PIK3C2B O00750 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
HDAC1 Q13547 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL13674719 0.89 FLT3 (0.41) FLT3PIK3CAMTORPIK3CGPIK3R1
SCHEMBL799171 0.83 MTOR (0.39) FLT3PIK3CAMTORPIK3CGYTHDC1
SCHEMBL13674720 0.82 PIK3CA (0.47) FLT3PIK3CAMTORPIK3CGPIK3R1
Bicarbonate SCHEMBL364127 0.76 PIK3CA (0.38) PIK3CAMTORPIK3CGPIK3R1PIK3CD
SCHEMBL336324 0.76 PIK3CA (0.43) FLT3PIK3CAMTORPIK3CGPIK3R1
SCHEMBL336325 0.75 MTOR (0.45) FLT3PIK3CAMTORPIK3CGPIK3R1
SCHEMBL9605491 0.75 MTOR (0.45) FLT3PIK3CAMTORPIK3CGPIK3R1
SCHEMBL362972 0.74 FLT3 (0.40) FLT3PIK3CAMTORPIK3CGYTHDC1
Bicarbonate SCHEMBL366205 0.74 PIK3CA (0.44) PIK3CAMTORPIK3CGPIK3R1PIK3CD
SCHEMBL13673773 0.73 FLT3 (0.47) FLT3PIK3CAMTORPIK3CGYTHDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071476-A1 MORPHOLINOPURINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-22 US disclosed
US-8097622-B2 Morpholinopurine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-17 US disclosed
EP-2336132-A1 MORPHOLINOPURINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2011-06-22 EP disclosed
US-20100130492-A1 MORPHOLINOPURINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130492-A1 MORPHOLINOPURINE DERIVATIVES MTOR, RICTOR, PIK3R1 FLT3 2698/4885PIK3CA 22/4885MTOR 1/4885
US-20120071476-A1 MORPHOLINOPURINE DERIVATIVES MTOR, RICTOR, PIK3R1 FLT3 2698/4885PIK3CA 22/4885MTOR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.